Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,472 total articles
Biohaven's decision to divest Opakalim rights to SK Biopharmaceuticals looks strategically sensible: it reduces near-term cash burn, sharpens focus on higher-value CNS programs, and improves optionality for shareholders. The market reaction should be constructive once deal terms and upfront cash are confirmed. Our trade: enter BHVN at $16.00, targe…
Qualcomm is dealing with persistent handset weakness that will keep near‑term results muted, but its pivot into data‑center and non‑handset businesses (targeting $40B by 2029) sets up a potential fundamental re‑rating in fiscal 2027. Valuation is reasonable today (P/E ~19, market cap ~ $172B) and free cash flow remains healthy. This trade targets a…
Diodes Inc. (DIOD) looks like a tactical long today. Recent results and balance-sheet strength suggest the company can fund margin-led expansion across industrial and automotive end markets, and the market is underestimating the probability that management's multiyear targets will start to show up in near-term guidance. This trade idea lays out an …
3M has stabilized operations, is generating meaningful free cash flow and sits in end markets that look set to recover. The balance sheet still carries leverage, but current pricing and technicals create a defined-risk mid-term long trade with clear upside if cyclical end markets reaccelerate.
L.B. Foster (FSTR) is a small-cap industrial with accelerating Rail and Infrastructure revenue, improving margin mix, and a compact balance sheet. Recent results and investor presentations point to a second-half recovery. At roughly $395M market cap, an EV/sales of 0.78 and about $47M in free cash flow suggest upside if management converts backlog …
We upgrade Big Yellow Group to Buy after re-testing the thesis in 2026. The case rests on steady demand for self-storage, healthy operating leverage, and a valuation that leaves room for upside if management executes on capital allocation. Entry, stop and target provided for a defined-risk trade across multiple horizons.
Bitcoin's bounce has restored a lot of headline value to bitcoin-linked stocks, but Strategy Inc (MSTR) has started to crystallize gains and change its treasury playbook. That shift, combined with a crowded long position, near-term technical overbought signals, and legal/financial overhangs, creates a compelling tactical short. This note lays out t…
Zhihu’s Q2 print showed a small revenue decline and a return to GAAP loss, but paid-content and IP operations expanded, operating expenses fell 13%, and management continued buybacks. At a market cap of roughly $268m and a PB of 0.45, the stock already prices in significant risk. This trade targets a rebound as margins stabilize and monetization fr…
Uber is trading well below its 52-week high after a pullback that looks more sentiment-driven than fundamental. With consensus-quality profitability (P/E ~17), $9.44B in free cash flow, and evidence of operational leverage, this is an actionable long trade: entry $76.75, stop $69.00, target $98.00, horizon ~180 trading days. Catalysts include activ…
Murphy USA (MUSA) is a trade to consider on the expectation that fuel margins will stay elevated into H2 2026. The stock trades with a mid-teens P/E, strong free cash flow and an attractive EV/EBITDA multiple for a high-return retailer. I lay out an entry, stop and target for a long-term tactical trade and the key risks that could derail the thesis…
Fortinet combines a durable, ASIC-accelerated security platform with strong cash generation and accelerating revenue, but it trades at a premium multiple and elevated EV/sales that limit upside. The trade: a measured mid-term long with defined risk controls while monitoring growth and margin trajectory.
MercadoLibre is trading well below its 52-week high after a correction that amplified concerns tied to Brazil. The company reported blowout revenue growth and strong fintech traction; balance sheet and cash flow strength support a tactical long. Entry at $1947.26, stop at $1800, target $2500 over a long term (180 trading days) horizon.
Rocket Lab (RKLB) is priced for perfection on Neutron, but the business can still deliver a credible quarter driven by launches, backlog and defense contracts. The trade: go long near $67 with a $57 stop and a $95 target over the next 45 trading days, while watching Neutron schedule and margins closely.
ACI Worldwide is a profitable, cash-generative payments software company trading at a reasonable multiple with a clear path to higher recurring revenue and margins. Recent M&A, product wins in open banking and a large addressable market for real-time payments support a long trade. Entry at $53.00, stop at $48.00, target $65.00 over a long-term (180…
Kazia Therapeutics ($KZIA) is a small-cap biotech where upcoming clinical readouts and regulatory interactions could validate paxalisib as a best-in-class PI3K/mTOR inhibitor for brain and selected solid tumors. At a market cap of roughly $167M and a current price near $14.60, the stock is priced for outcome sensitivity. This trade targets asymmetr…
Teradyne is transitioning from a cyclical semiconductor-test supplier to a structural beneficiary of AI-driven semiconductor and robotics demand. Strong Q2 results, widening guidance, and improving free cash flow create a favorable risk/reward around $370. Trade plan: enter at $370.00, stop $330.00, target $460.00 (primary) over a 180-trading-day h…
Vontier’s recent top-line stagnation masks a healthier earnings and free-cash-flow profile. With FCF of $384.8M, EPS near $2.57 and an EV/EBITDA of 8.9, the balance between operational leverage and a still-manageable balance sheet makes a tactical long where upside to analyst targets looks reachable and downside is containable with a tight stop.
TotalEnergies is trading at $87.26 with a market cap near $198B, a P/E of 10.6 and a 4.4% dividend yield. The company is benefiting from elevated commodity realizations and operational progress on projects like GranMorgu, while integrating AI and digital partners to shave costs. We favor a mid-term long (45 trading days) entry designed to capture d…
Nvidia's 08/26/2026 quarter blew past expectations: $96.2B revenue (106% YoY), $29.2B adjusted net income, and management guiding to $108B for the next quarter. The market has briefly priced in deceleration despite record profits; that disconnect creates an asymmetric risk/reward for a disciplined long with a $223 entry, $200 stop and $300 target o…
Cogent Biosciences (COGT) has lined up three regulatory filings for bezuclastinib across Non-Advanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM) and GIST. FDA acceptance and robust SUMMIT data support a tactical long into the late-2026 decision window. Entry at $37.00, stop at $30.00, target $60.00, long term (180 trad…
Joby has industry-leading progress on FAA certification and deep pockets from partners, yet the stock remains priced for perfection (price-to-sales ~61x) and management's recent capital actions have increased dilution risk. Trade the squeeze between regulatory headlines and financing overhang: short with a tight stop and a mid-term horizon to captu…
Quanta Services (PWR) has been hit by a rapid derating from its 2026 highs. The selloff creates a favorable risk-reward: the company sports a near-record backlog, healthy free cash flow and shareholder-friendly actions, while valuation and sentiment have pulled back enough to justify a tactical long. This trade idea lays out an entry at $620.00, a …
Synopsys is the core EDA and IP provider quietly baked into the chip design flows that power next-generation AI chips. With a $78.5B market cap, $2.75B in free cash flow and partnership momentum around agentic engineering toolkits, the stock looks like a tactical buy on strength in design automation demand. This trade plan buys the stock near curre…
GSK ($51.44) combines a resilient commercial franchise, meaningful vaccine exposure and a mid-teens P/E with a 3.4% yield. Technicals are neutral-to-bullish and the company sits squarely in expanding vaccine markets (influenza, HPV). I recommend a long trade sized for a diversified portfolio: entry $51.40, primary target $62.00, stop loss $48.00, h…
Siemens Energy has pushed through a painful restructuring cycle. With improved execution across Gas, Grid, and Siemens Gamesa, the stock looks primed for a tactical long. This trade targets a recovery driven by backlog conversion, better margin trajectory and falling working capital pressure.
